Viridian Therapeutics, Inc.
VRDN
$12.38
-$0.43-3.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -16.28% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -16.28% | |||
| Cost of Revenue | -97.59% | -- | |||
| Gross Profit | 97.62% | -277,055.81% | |||
| SG&A Expenses | 9.75% | 8.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.30% | 4.76% | |||
| Operating Income | -7.31% | -4.78% | |||
| Income Before Tax | -9.01% | -3.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.01% | -3.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.01% | -3.96% | |||
| EBIT | -7.31% | -4.78% | |||
| EBITDA | -7.33% | -4.80% | |||
| EPS Basic | -279.31% | 80.16% | |||
| Normalized Basic EPS | -6.95% | 13.19% | |||
| EPS Diluted | -279.31% | 80.16% | |||
| Normalized Diluted EPS | -6.95% | 13.19% | |||
| Average Basic Shares Outstanding | 1.61% | 20.52% | |||
| Average Diluted Shares Outstanding | 1.61% | 20.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||